Advancing Supply Chain Resilience in Europe’s O...

By HEOR Staff Writer

April 28, 2026

In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, ...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
Escalating Public Spending: Semaglutide Off-Label Use Sparks €250 Million Fra...
Safeguarding Access: Navigating Pharmaceutical Cost Pressures in Portugal
100% Tariffs Impacting Pharmaceutical Manufacturing and National Security
EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceuti...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation